NZ756749A - Methods and compositions comprising purified recombinant polypeptides - Google Patents

Methods and compositions comprising purified recombinant polypeptides

Info

Publication number
NZ756749A
NZ756749A NZ756749A NZ75674914A NZ756749A NZ 756749 A NZ756749 A NZ 756749A NZ 756749 A NZ756749 A NZ 756749A NZ 75674914 A NZ75674914 A NZ 75674914A NZ 756749 A NZ756749 A NZ 756749A
Authority
NZ
New Zealand
Prior art keywords
methods
purified recombinant
recombinant polypeptides
compositions
antibodies
Prior art date
Application number
NZ756749A
Other languages
English (en)
Inventor
X Christopher Yu
Fischer Saloumeh Kadkhodayan
Susan C Fisher
John Lowe
Atia Naim
Ailen M Sanchez
Christopher A Teske
Martin Vanderlaan
Annamarie Amurao
Jayme Franklin
Corazon Victa
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NZ756749A publication Critical patent/NZ756749A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ756749A 2013-09-13 2014-09-12 Methods and compositions comprising purified recombinant polypeptides NZ756749A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361877517P 2013-09-13 2013-09-13
NZ718144A NZ718144A (en) 2013-09-13 2014-09-12 Methods and compositions comprising purified recombinant polypeptides

Publications (1)

Publication Number Publication Date
NZ756749A true NZ756749A (en) 2022-05-27

Family

ID=52666315

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ756749A NZ756749A (en) 2013-09-13 2014-09-12 Methods and compositions comprising purified recombinant polypeptides
NZ718144A NZ718144A (en) 2013-09-13 2014-09-12 Methods and compositions comprising purified recombinant polypeptides
NZ756750A NZ756750A (en) 2013-09-13 2014-09-12 Methods and compositions comprising purified recombinant polypeptides

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ718144A NZ718144A (en) 2013-09-13 2014-09-12 Methods and compositions comprising purified recombinant polypeptides
NZ756750A NZ756750A (en) 2013-09-13 2014-09-12 Methods and compositions comprising purified recombinant polypeptides

Country Status (18)

Country Link
US (8) US9920120B2 (cg-RX-API-DMAC7.html)
EP (3) EP3043820A4 (cg-RX-API-DMAC7.html)
JP (4) JP6751344B2 (cg-RX-API-DMAC7.html)
KR (2) KR102571391B1 (cg-RX-API-DMAC7.html)
CN (2) CN105722532A (cg-RX-API-DMAC7.html)
AR (3) AR097651A1 (cg-RX-API-DMAC7.html)
AU (2) AU2014318615B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016004413A2 (cg-RX-API-DMAC7.html)
CA (2) CA3184564A1 (cg-RX-API-DMAC7.html)
HK (1) HK1225988A1 (cg-RX-API-DMAC7.html)
IL (2) IL244149B2 (cg-RX-API-DMAC7.html)
MX (3) MX382393B (cg-RX-API-DMAC7.html)
MY (2) MY176026A (cg-RX-API-DMAC7.html)
NZ (3) NZ756749A (cg-RX-API-DMAC7.html)
RU (1) RU2671481C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201802525QA (cg-RX-API-DMAC7.html)
WO (1) WO2015038888A1 (cg-RX-API-DMAC7.html)
ZA (4) ZA201601965B (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201506494XA (en) 2013-03-15 2015-09-29 Glaxosmithkline Ip No 2 Ltd Methods for purifying antibodies
PL2970378T3 (pl) 2013-03-15 2021-12-06 Biogen Ma Inc. Chromatografia oddziaływań hydrofobowych białek w warunkach bez soli
JP6751344B2 (ja) * 2013-09-13 2020-09-02 ジェネンテック， インコーポレイテッド 精製された組み換えポリペプチドを含む方法及び組成物
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
TW201702380A (zh) 2015-02-27 2017-01-16 再生元醫藥公司 宿主細胞蛋白質修飾
KR20180048731A (ko) * 2015-08-20 2018-05-10 제넨테크, 인크. 재조합 폴리펩티드를 제조하기 위한 fkpa의 정제 및 그의 용도
KR20240121902A (ko) * 2015-08-21 2024-08-09 에프. 호프만-라 로슈 아게 친화성 크로마토그래피에서의 숙주 세포 단백질 감소 방법
HK1251583A1 (zh) 2015-08-21 2019-02-01 F. Hoffmann-La Roche Ag 在亲和层析中减少宿主细胞蛋白的方法
SG11201808992UA (en) * 2016-04-14 2018-11-29 Lonza Ag Compositions and methods for the detection of host cell proteins
EA037960B1 (ru) 2016-04-27 2021-06-15 Эббви Инк. Способ лечения эозинофильного эзофагита с применением антитела против il-13
CA3031028C (en) * 2016-07-25 2024-02-13 Lu Wang Affinity chromatography wash buffer
WO2018034885A1 (en) 2016-08-16 2018-02-22 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
DK3510042T3 (da) 2016-09-07 2024-06-10 Glaxosmithkline Ip Dev Ltd Fremgangsmåde til rensning af antistoffer
BR112019004938A2 (pt) * 2016-10-06 2019-06-25 Glaxosmithkline Ip Dev Ltd anticorpo igg4 variante, linhagem celular, métodos para modificação de um anticorpo igg para reduzir a ligação a uma impureza de processo e para produção de um anticorpo igg4 com ligação reduzida à proteína de célula hospedeira, e, composição.
MX2019004316A (es) 2016-10-25 2019-08-05 Regeneron Pharma Metodos y sistemas para analisis de datos cromatograficos.
WO2018116198A1 (en) 2016-12-23 2018-06-28 Serum Institute Of India Private Limited Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
CN111201042B (zh) 2017-09-19 2024-05-10 里珍纳龙药品有限公司 减少粒子形成的方法以及由其形成的组合物
TW202003555A (zh) * 2018-03-07 2020-01-16 英商葛蘭素史克智慧財產發展有限公司 用於純化重組多肽之方法
TW202448568A (zh) 2018-07-02 2024-12-16 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
EP3826743A4 (en) * 2018-07-25 2022-09-14 Merck Sharp & Dohme Corp. METHODS FOR SEPARATION OF HOST CELL LIPASES FROM A PRODUCTION PROTEIN IN CHROMATOGRAPHIC METHODS
EP3916001A4 (en) 2019-01-23 2022-10-19 Daiichi Sankyo Company, Limited ONE-STEP PROCEDURE FOR PURIFICATION OF ANTIBODIES USING ACTIVATED CARBON MATERIAL
WO2020157749A1 (en) * 2019-01-29 2020-08-06 Bnai Zion Medical Center Anti il-17 antibody for use in treating chronic spontaneous urticaria
AU2020257220A1 (en) * 2019-04-17 2021-11-11 Regeneron Pharmaceuticals, Inc. Identification of host cell proteins
JP7578619B2 (ja) * 2019-05-21 2024-11-06 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ホスト細胞タンパク質の同定および定量方法
US20220314142A1 (en) * 2019-07-01 2022-10-06 Pfizer Inc. Improvements to wash solutions for protein a chromatography in an antibody purification process
CN114555622A (zh) * 2019-10-04 2022-05-27 默克专利股份有限公司 蛋白质的纯化和病毒灭活
AU2021213153A1 (en) * 2020-01-29 2022-08-04 Merck Sharp & Dohme Llc Methods of separating host cell lipases from an anti-LAG3 antibody production
JP2024517779A (ja) * 2021-05-03 2024-04-23 アジレント・テクノロジーズ・インク キメラ免疫原および特定のエピトープに対するポリクローナル抗体の作製方法
CN119497609A (zh) * 2022-05-02 2025-02-21 瑞泽恩制药公司 降低脂肪酶活性的方法
PE20251639A1 (es) 2022-06-17 2025-06-24 Apogee Biologics Inc Anticuerpos que se unen a interleuquina 13 y metodos de uso
EP4637820A1 (en) * 2022-12-19 2025-10-29 Eli Lilly and Company Methods of reducing contaminants in protein purification
WO2025049345A1 (en) 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
CN117169518B (zh) * 2023-11-03 2024-01-19 赛德特(北京)生物工程有限公司 T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods

Family Cites Families (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1319315A (en) 1969-06-19 1973-06-06 Citizen Watch Co Ltd Calendar timepiece
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3422247A1 (de) 1984-06-15 1985-12-19 Pfeifer & Langen, 5000 Köln Gluco-oligosaccharid-gemisch und verfahren zu seiner herstellung
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5359037A (en) 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US4847745A (en) 1988-11-16 1989-07-11 Sundstrand Corp. Three phase inverter power supply with balancing transformer
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5011778A (en) 1989-05-23 1991-04-30 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE136906T1 (de) 1989-12-20 1996-05-15 Schering Corp Antikörperantagonisten gegen humanes interleukin- 4
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
HU217099B (hu) 1991-03-29 1999-11-29 Elf Sanofi Sa. Eljárás citokin típusú aktivitással rendelkező fehérje, azt kódoló rekombináns DNS-szekvencia és a megfelelő transzformált sejtek és mikroorganizmusok előállítására
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5965709A (en) 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
US5994514A (en) 1991-08-14 1999-11-30 Genentech, Inc. Immunoglobulin variants
US6329509B1 (en) 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
ATE295420T1 (de) 1992-02-06 2005-05-15 Chiron Corp Marker für krebs und biosynthetisches bindeprotein dafür
WO1993015766A1 (en) 1992-02-10 1993-08-19 Seragen, Inc. Desensitization to specific allergens
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5550045A (en) 1992-05-15 1996-08-27 Unilever Patent Holdings, B.V. Cloning and expression of DNA encoding a ripening form of a polypeptide having rhamnogalcturonase activity
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
WO1994004680A1 (en) 1992-08-21 1994-03-03 Schering Corporation Human interleukin-13
US5596072A (en) 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
EP0866130B1 (en) 1993-05-17 2010-07-21 Genentech, Inc. CHO cell sialidase by recombinant DNA technology
IL110855A (en) 1993-09-02 1999-04-11 Dartmouth College Methods for inducing antigen-specific t cell tolerance
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6037453A (en) 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US6518061B1 (en) 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6911530B1 (en) 1995-10-23 2005-06-28 Amrad Operations, Pty., Ltd. Haemopoietin receptor and genetic sequences encoding same
CA2238080C (en) 1995-10-23 2012-03-13 Amrad Operations Pty. Ltd. A novel haemopoietin receptor and genetic sequences encoding same
FR2742156A1 (fr) 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
WO1997029131A1 (en) 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US7078494B1 (en) 1996-03-01 2006-07-18 Genetics Institute, Llc Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
WO1997047742A1 (en) 1996-06-12 1997-12-18 Smithkline Beecham Corporation Hr-1 receptor
WO1998010638A1 (en) 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Therapeutic molecules
EP0950067B1 (en) 1996-11-27 2007-08-29 Genentech, Inc. Affinity purification of polypeptide on protein a matrix
US6743604B1 (en) 1996-12-13 2004-06-01 Smithkline Beecham Corporation Substances and their uses
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
JP2001508441A (ja) 1997-01-10 2001-06-26 バイオジェン インコーポレイテッド 抗ｃｄ４０ｌ化合物での狼瘡腎炎の処置
BR9806793A (pt) 1997-01-22 2000-05-16 Univ Texas Processos e composições de fator tissular para coagulação e tratamento de tumores.
US6576232B1 (en) 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
US6482403B1 (en) 1998-05-29 2002-11-19 Heska Corporation Caniney IL-13 immunoregulatory proteins and uses thereof
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
GB9820014D0 (en) 1998-09-14 1998-11-04 Cancer Res Campaign Tech Receptor antagonists and uses thereof
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
DE19848026A1 (de) 1998-10-17 2000-04-20 Bayer Ag Verfahren zur Herstellung von Bis(4-hydroxyaryl)alkanen
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
NZ512942A (en) 1998-12-14 2004-01-30 Univ Johns Hopkins Polynucleotides encoding the IL-13 binding chains of the interleukin receptor, pharmaceutical compositions comprising the protein and methods of identifying inhibitors
AU2750800A (en) 1999-02-01 2000-08-18 Amgen Canada Inc. Materials and methods to inhibit hodgkin and reed sternberg cell growth
EP1263785A2 (en) 1999-11-11 2002-12-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Mutated il-13 molecules and their uses
US20100041039A1 (en) 2000-01-15 2010-02-18 Synageva Biopharma Corp. Analysis of nucleic acid obtained from nucleated red blood cells
MXPA02008145A (es) 2000-02-24 2004-04-05 Univ Washington Anticuerpos humanizados que secuestran al peptido beta amiloide.
JP3926153B2 (ja) 2000-03-03 2007-06-06 協和醗酵工業株式会社 遺伝子組換え抗体およびその抗体断片
CN1323812A (zh) 2000-05-16 2001-11-28 上海博德基因开发有限公司 一种新的多肽——人白细胞介素－13(il－13)受体11和编码这种多肽的多核苷酸
AU2002210918B2 (en) 2000-10-20 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Degraded agonist antibody
DK1333850T3 (da) 2000-10-20 2008-12-01 Genetics Inst Anvendelse af IL-13-inhibitorer til behandling af tumorer
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
ATE519783T1 (de) 2000-12-22 2011-08-15 Grad Carole Legal Representative Of Kaplan Howard ßPHAGE DISPLAYß BIBLIOTHEKE VON MENSCHLICHEN VH FRAGMENTEN
US20040242851A1 (en) 2001-06-26 2004-12-02 Zhenping Zhu Bispecific antibodies that bind to vegf receptors
US20030023555A1 (en) 2001-07-26 2003-01-30 Cashworks, Inc. Method and system for providing financial services
MXPA04001894A (es) 2001-08-31 2005-09-08 Kyowa Hakko Kogyo Kk Anticuerpo humano injertado en una cdr y fragmento de dicho anticuerpo.
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP1578912A4 (en) 2001-10-26 2007-12-26 Centocor Inc IL-13 MUTEIN PROTEINS, ANTIBODIES, COMPOSITIONS, METHODS AND USES
US20030235555A1 (en) 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
ATE419007T1 (de) 2001-11-07 2009-01-15 Cytos Biotechnology Ag Antigenraster welche il-5, il-13 oder eotaxin präsentieren, zur behandlung von allergischen, eosinophilen erkrankungen
AU2003210802B2 (en) 2002-02-05 2009-09-10 Genentech Inc. Protein purification
US20040060102A1 (en) 2002-04-10 2004-04-01 Interspiro, Inc. Garments for biological, chemical and fire protection
DK1501369T3 (en) 2002-04-26 2015-09-28 Genentech Inc Non-affinity purification of proteins
EP1552462B1 (en) 2002-06-14 2011-03-23 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods of treating and preventing colitis involving il-13 and nk-t cells
JP2006503018A (ja) 2002-08-30 2006-01-26 グラクソ　グループ　リミテッド ワクチン
AU2003259358A1 (en) 2002-08-30 2004-03-19 Claire Ashman Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
DE602004027348D1 (de) 2003-02-10 2010-07-08 Applied Molecular Evolution Abeta-bindende moleküle
US7157276B2 (en) 2003-06-20 2007-01-02 Biogen Idec Inc. Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
DE602004017726D1 (de) 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
DK2805728T3 (da) 2003-12-23 2020-04-20 Genentech Inc Hidtil ukendte anti-IL13-antistoffer og anvendelser deraf
RU2401277C2 (ru) 2004-01-07 2010-10-10 Чирон Корпорейшн Не мышиное анти-m-csf-антитело (варианты), его получение и использование
WO2005071410A1 (en) 2004-01-13 2005-08-04 Tanox, Inc. Detecting and quantifying host cell proteins in recombinant protein products
CN1965082A (zh) 2004-02-06 2007-05-16 尼莫克斯股份有限公司 人源化抗体
UA93181C2 (ru) 2004-02-23 2011-01-25 Эли Лилли Энд Компани СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛА K Ab ПЕПТИДУ
US20070037966A1 (en) * 2004-05-04 2007-02-15 Novo Nordisk A/S Hydrophobic interaction chromatography purification of factor VII polypeptides
ES2339953T5 (es) 2004-05-04 2020-05-06 Novo Nordisk Healthcare Ag Glicoformas de factor VII ligadas a O y método de fabricación
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
MX2007004437A (es) 2004-10-22 2007-06-20 Amgen Inc Metodos para el repliegue de anticuerpos recombinantes.
RU2418411C2 (ru) 2004-12-24 2011-05-20 Коммонвелт Сайентифик Энд Индастриал Рисерч Организейшн Композиции пестицидов и способ их получения и применения
CN104610422A (zh) 2005-03-11 2015-05-13 惠氏公司 弱分配层析的方法
KR20080006601A (ko) 2005-04-11 2008-01-16 메다렉스, 인코포레이티드 단백질 정제 방법
JP5270337B2 (ja) 2005-06-17 2013-08-21 ヤンセン アルツハイマー イミュノセラピー 抗Ａβ抗体を精製する方法
JP3982545B2 (ja) 2005-09-22 2007-09-26 ダイキン工業株式会社 空気調和装置
PL1942939T5 (pl) * 2005-09-30 2021-10-11 Medimmune Limited Kompozycja przeciwciała interleukiny-13
EP1957530A2 (en) 2005-10-21 2008-08-20 Novartis AG Human antibodies against il13 and therapeutic uses
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
US7667557B2 (en) 2005-12-06 2010-02-23 Tdk Corporation Thin-film bandpass filter using inductor-capacitor resonators
UY30003A1 (es) 2005-12-12 2007-08-31 Hoffmann La Roche Anticuerpos glicosilados en la region variable
MX358175B (es) 2005-12-12 2018-08-08 Ac Immune Sa Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas.
EP1966244B1 (en) 2005-12-30 2012-03-21 Merck Patent GmbH Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130
US7563875B2 (en) 2006-03-20 2009-07-21 The United States of America as represented by the Sercretary of the Army Recombinant chimeric human anti-botulinum antibodies
EP2738178A1 (en) * 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
MX2008013394A (es) 2006-04-21 2008-10-31 Wyeth Corp Metodos para tamizado de alta emision de lineas celulares.
US7892544B2 (en) 2006-07-14 2011-02-22 Ac Immune Sa Humanized anti-beta-amyloid antibody
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
KR20090068266A (ko) 2006-09-21 2009-06-25 베레늄 코포레이션 포스포리파제, 그를 코딩하는 핵산 그리고 그를 제조 및 이용하는 방법
BRPI0719763A2 (pt) 2006-10-02 2014-01-28 Ac Immune Sa Anticorpo, molécula de ácido nucleico, vetor de expressão, célula, composição, mistura, uso de um anticorpo quimérico ou um fragmento do mesmo ou um anticorpo humanizado ou um fragmento do mesmo e/ou uma parte funcional e/ou uma composição farmacêutica ou uma mistura, métodos para a preparação de uma composição farmacêutica ou de uma mistura, para prevenir, tratar ou aliviar os efeitos de uma doença, de diagnóstico de uma doença ou condição associada com amilóide em um paciente e de determinação do grau da carga de placa amiloidogênica em um tecido e/ou fluidos corporais, kits de teste para a detecção e diagnóstico de doenças e condições associadas com amilóide, região variável de cadeia leve, região variável de cadeia pesada, linhagem de célula, gene de anticorpo, e, métodos para desagregar fibras de beta-amilóide pré formadas, para prevenir a degradação de neurônio induzida por abeta, para diagnosticar uma predisposição a uma doença ou condição associada com amilóide em um paciente, para monitorar doença residual mínima em um paciente, para prognosticar a responsividade de um paciente que é tratado com um anticorpo ou uma composição de vacina, para reduzir a carga de placa no cérebro de um animal, para reduzir a quantidade de placas no cérebro de um animal, para diminuir a quantidade total de abeta solúvel no cérebro de um animal e para reter ou aumentar a capacidade de memória cognitiva em um mamífero.
MX2009003562A (es) 2006-10-04 2009-04-15 Genentech Inc Ensayo elisa para la deteccion de vegf.
US8383350B1 (en) 2006-12-20 2013-02-26 Merck Sharp & Dohme Corp. Assay for detection of IL-10 antibodies
AR064826A1 (es) 2007-01-09 2009-04-29 Wyeth Corp Formulaciones de anticuerpos anti-il-13 y usos de los mismos. dispositivos, parche y jeringa
WO2008140455A1 (en) 2007-05-15 2008-11-20 Tanox, Inc. Treatment of radiation and chemo-therapy induced fibrosis using novel anti-il 13 monoclonal antibodies
PE20090831A1 (es) 2007-06-12 2009-07-10 Ac Immune Sa Anticuerpo monoclonal
PE20131334A1 (es) 2007-06-12 2013-11-13 Ac Immune Sa Anticuerpo igg1 humanizado
US9433922B2 (en) 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
PT2238166E (pt) 2007-10-05 2014-02-11 Genentech Inc Utilização do anticorpo anti-amilóide beta em doenças oculares
RU2542967C2 (ru) 2007-10-05 2015-02-27 Дженентек, Инк. Применение антитела против амилоида бета при глазных заболеваниях
NZ601858A (en) 2007-10-05 2014-03-28 Genentech Inc Methods and compositions for diagnosis and treatment of amyloidosis
WO2009058769A1 (en) * 2007-10-30 2009-05-07 Schering Corporation Purification of antibodies containing hydrophobic variants
MX348362B (es) 2008-03-31 2017-06-07 Genentech Inc * Composiciones y metodos para tratar y diagnosticar asma.
US8344115B2 (en) 2008-04-21 2013-01-01 Chan-Sui Pang, legal representative Immunoassay for specific determination of S-adenosylmethionine and analogs thereof in biological samples
NZ588674A (en) 2008-05-05 2013-02-22 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
US9416192B2 (en) 2008-08-05 2016-08-16 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancers
US8790642B2 (en) * 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
GB0818674D0 (en) 2008-10-10 2008-11-19 Univ Bath Materials and methods for resolving polyhydric species by electrophoresis
RU2011120178A (ru) 2008-10-20 2012-11-27 Эбботт Лэборетриз Антитела, которые связываются с il-12, и способы их очистки
AU2009307737B2 (en) 2008-10-20 2015-07-23 Abbvie Inc. Viral inactivation during purification of antibodies
RU2514657C2 (ru) 2008-10-20 2014-04-27 Эббви Инк, Способ получения препарата антитела против il-18 или его антигенсвязывающей части (варианты)
EP2350127B1 (en) 2008-10-20 2015-01-28 AbbVie Inc. Isolation and purification of antibodies using protein a affinity chromatography
CN101979404B (zh) 2008-12-09 2015-01-14 厦门大学 H5亚型禽流感病毒保守中和表位模拟肽及其用途
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
WO2011010940A1 (en) 2009-07-19 2011-01-27 Serguei Zavtrak Solar electric power generator
EP2462158B1 (en) 2009-08-06 2018-01-10 F. Hoffmann-La Roche AG Method to improve virus removal in protein purification
CN102574924A (zh) 2009-09-03 2012-07-11 先灵公司 抗-gitr抗体
UA109884C2 (uk) 2009-10-16 2015-10-26 Поліпептид, що має активність ферменту фосфатидилінозитол-специфічної фосфоліпази с, нуклеїнова кислота, що його кодує, та спосіб його виробництва і застосування
SI3037104T1 (sl) * 2009-10-20 2020-10-30 Abbvie Inc. Izolacija in prečiščevanje protiteles anti-IL-13 z uporabo afinitetne kromatografije beljakovine A
SI3342786T1 (sl) 2010-01-29 2022-01-31 Chugai Seiyaku Kabushiki Kaisha Anti-DLL3 protitelo
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
GEP201706660B (en) 2010-03-04 2017-04-25 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
EP3181149A1 (en) 2010-05-14 2017-06-21 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd47
PH12012502231A1 (en) 2010-05-17 2013-02-04 Livtech Inc Anti-human trop-2 antibody having antitumor activity in vivo
SI2575847T2 (sl) 2010-05-25 2022-08-31 F. Hoffmann-La Roche Ag Tehnike čiščenja polipeptidov
WO2012006341A2 (en) 2010-07-06 2012-01-12 Aveo Pharmaceuticals, Inc. Anti-ron antibodies
MY164579A (en) 2010-07-30 2018-01-15 Ac Immune Sa Safe and functional humanized antibodies
CA2811087A1 (en) 2010-09-29 2012-04-12 Genentech, Inc. Antibody compositions and methods of use
DK2646470T3 (en) * 2010-11-30 2017-05-08 Hoffmann La Roche ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH LOW AFFINITY AND ITS USE FOR TRANSPORTING THERAPEUTIC SCFV OVER THE BLOOD-BRAIN BARRIER
TWI666447B (zh) 2010-12-16 2019-07-21 建南德克公司 關於ｔｈ２抑制作用之診斷及治療
EP3403672A1 (en) 2011-04-20 2018-11-21 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
WO2013028330A2 (en) * 2011-08-19 2013-02-28 Emd Millipore Corporation Methods of reducing level of one of more impurities in a sample during protein purification
US20140288278A1 (en) 2011-10-31 2014-09-25 Joseph Nti-Gyabaah Chromatography process for resolving heterogeneous antibody aggregates
CN116077644A (zh) * 2011-10-31 2023-05-09 弗·哈夫曼-拉罗切有限公司 抗体制剂
CN104066748A (zh) * 2011-11-21 2014-09-24 霍夫曼-拉罗奇有限公司 抗c-met抗体的纯化
KR101498771B1 (ko) 2011-12-15 2015-03-09 한화케미칼 주식회사 항체의 정제 방법
WO2013120497A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
SG11201405273YA (en) 2012-02-29 2014-09-26 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
JP6751344B2 (ja) * 2013-09-13 2020-09-02 ジェネンテック， インコーポレイテッド 精製された組み換えポリペプチドを含む方法及び組成物
EP3044323B1 (en) 2013-09-13 2022-04-06 F. Hoffmann-La Roche AG Methods for detecting and quantifying host cell protein in cell lines
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography

Also Published As

Publication number Publication date
KR102571391B1 (ko) 2023-08-29
WO2015038888A9 (en) 2016-03-17
JP6982027B2 (ja) 2021-12-17
EP3043820A4 (en) 2017-07-12
US10597446B2 (en) 2020-03-24
EP3043820A1 (en) 2016-07-20
AR133787A2 (es) 2025-11-05
AU2014318615A9 (en) 2016-06-16
EP4331605A3 (en) 2024-05-22
CA2921999A1 (en) 2015-03-19
JP2022036971A (ja) 2022-03-08
MX2021005364A (es) 2021-06-30
CN105722532A (zh) 2016-06-29
JP2024059617A (ja) 2024-05-01
AR118560A2 (es) 2021-10-20
JP7489953B2 (ja) 2024-05-24
US10597447B2 (en) 2020-03-24
US20250250333A1 (en) 2025-08-07
AU2014318615B2 (en) 2020-03-12
IL244149A0 (en) 2016-04-21
CN120904322A (zh) 2025-11-07
KR102373930B1 (ko) 2022-03-11
AR097651A1 (es) 2016-04-06
RU2016108828A3 (cg-RX-API-DMAC7.html) 2018-05-29
US20210115126A1 (en) 2021-04-22
IL244149B1 (en) 2025-05-01
CA2921999C (en) 2023-03-21
ZA201601965B (en) 2018-11-28
ZA202201361B (en) 2023-11-29
MY193481A (en) 2022-10-17
ZA202101142B (en) 2022-09-28
US10494429B2 (en) 2019-12-03
US11667706B2 (en) 2023-06-06
JP6751344B2 (ja) 2020-09-02
MX2021005358A (es) 2021-06-30
US20180291095A1 (en) 2018-10-11
MX382393B (es) 2025-03-13
NZ756750A (en) 2022-05-27
JP2019178139A (ja) 2019-10-17
IL244149B2 (en) 2025-09-01
EP4331605A2 (en) 2024-03-06
HK1225988A1 (zh) 2017-09-22
ZA201801849B (en) 2021-07-28
AU2020200502B2 (en) 2022-03-10
NZ718144A (en) 2022-05-27
SG10201802525QA (en) 2018-04-27
US9920120B2 (en) 2018-03-20
US20230250165A1 (en) 2023-08-10
KR20220034930A (ko) 2022-03-18
AU2020200502B9 (en) 2022-03-24
SG11201601823TA (en) 2016-04-28
MX2016003202A (es) 2016-06-07
KR20160052724A (ko) 2016-05-12
US10822404B2 (en) 2020-11-03
AU2020200502A1 (en) 2020-02-13
RU2016108828A (ru) 2017-10-18
US20180273615A1 (en) 2018-09-27
MY176026A (en) 2020-07-22
US12312399B2 (en) 2025-05-27
US20160319012A1 (en) 2016-11-03
AU2014318615A1 (en) 2016-04-21
WO2015038888A1 (en) 2015-03-19
US20180291094A1 (en) 2018-10-11
US20180312585A1 (en) 2018-11-01
BR112016004413A2 (pt) 2017-10-17
IL320195A (en) 2025-06-01
JP2016539176A (ja) 2016-12-15
RU2671481C2 (ru) 2018-10-31
EP3683232A1 (en) 2020-07-22
CA3184564A1 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
NZ756749A (en) Methods and compositions comprising purified recombinant polypeptides
Ramalingam et al. Enhanced protection from fibrosis and inflammation in the combined absence of IL‐13 and IFN‐γ
Chung et al. Chemokines in renal injury
Hesse et al. Subcutaneous immunotherapy with purified Der p1 and 2 suppresses type 2 immunity in a murine asthma model
AU2018261588A1 (en) Methods of treatment using a JAK inhibitor compound
Liou et al. Casticin inhibits interleukin-1β–induced ICAM-1 and MUC5AC expression by blocking NF-κB, PI3K-Akt, and MAPK signaling in human lung epithelial cells
NO341523B1 (no) Benzoimidazol-2-ylpyrimidiner og -pyraziner som modulatorer av histamin H4-reseptoren, farmasøytisk sammensetning samt anvendelse
HRP20211932T1 (hr) Humana antitijela na fel d1 i postupci njihove upotrebe
MX2014002393A (es) Inhibidores de rock suaves, novedosos.
Bottasso et al. The immuno‐endocrine component in the pathogenesis of tuberculosis
JP2019116499A (ja) Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法
Gao et al. Lentivirus expressing soluble ST2 alleviates bleomycin-induced pulmonary fibrosis in mice
MX2021013427A (es) Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33.
Al-Sajee et al. Antialarmins for treatment of asthma: future perspectives
Pelaia et al. Type 2 severe asthma: pathophysiology and treatment with biologics
RU2013157398A (ru) Композиция
He et al. Therapeutic effects of DZ2002, a reversible SAHH inhibitor, on lupus-prone NZB× NZW F1 mice via interference with TLR-mediated APC response
Pan et al. Epidemiology and treatment of psoriasis: a Chinese perspective
Sarir et al. Combination of fluticasone propionate and salmeterol potentiates the suppression of cigarette smoke-induced IL-8 production by macrophages
EP3143404A1 (en) Assay for detecting th1 and th2 cell populations
Moon et al. Blocking interleukin-17 attenuates enhanced inflammation by staphylococcal enterotoxin B in murine allergic rhinitis model
Nishimura et al. Selective suppression of Th2 cell-mediated lung eosinophilic inflammation by anti-major facilitator super family domain containing 10 monoclonal antibody
Wang et al. IL-33 amplifies airways inflammation in a murine surrogate of asthma putatively via activation of dendritic cells
Pescitelli et al. Tuberculosis reactivation risk in dermatology
Ruperto et al. OP0215 Subcutaneous Abatacept in Patients with Polyarticular Juvenile Idiopathic Arthritis and Inadequate Response To Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Efficacy and Safety

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 SEP 2024 BY ANAQUA SERVICES

Effective date: 20230823

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 SEP 2025 BY ANAQUA SERVICES

Effective date: 20240820

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 SEP 2026 BY ANAQUA SERVICES

Effective date: 20250820